Results 231 to 240 of about 160,542 (279)

Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study. [PDF]

ESMO Open
Cigliola A, Maiorano BA, Rossari F, Tateo V, Mercinelli C, Dizman N, Colecchia M, De Cobelli F, Larcher A, Rosiello G, Briganti A, Montorsi F, Capitanio U, Spiess PE, Agarwal N, Pal SK, Necchi A.   +16 more
europepmc   +1 more source

Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer. [PDF]

Cancer Res Commun
Schlachter NM, Miller EJ, Anker JF, Galsky MD, Palmer AC.   +4 more
europepmc   +1 more source

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors

Cancer Science, EarlyView.
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama   +2 more
wiley   +1 more source

Peripheral CD8+ T Cell Dynamics and Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Following Bronchoscopic Cryotherapy and Pembrolizumab-Based Therapy. [PDF]

Cancers (Basel)
Vasiliauskas G, Žemaitė E, Skrodenienė E, Poškienė L, Miliauskas S, Žemaitis M.   +5 more
europepmc   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Pathological complete response following systemic therapy with carboplatin-paclitaxel plus pembrolizumab for initially unresectable mismatch repair-deficient advanced endometrial cancer: two case reports. [PDF]

Gynecol Oncol Rep
Uetake N, Miura S, Suzuki Y, Kojima N, Kondoh C, Horie K.   +5 more
europepmc   +1 more source

Human IDO2 exhibits unique binding affinities distinct to those of human IDO1

The FEBS Journal, EarlyView.
Although indoleamine 2,3‐dioxygenase 2 (IDO2) is highly homologous to IDO1, it displays markedly lower catalytic activity. We found that IDO2 binds L‐tryptophan (L‐Trp) in a flipped orientation stabilized by the IDO2‐specific residue His143. Replacement of His143 with the IDO1‐equivalent tyrosine restored an IDO1‐like binding mode and increased ...
Shunsuke Nogi, Ayumu Takahashi, So Murakami, Nami Adachi, Tina Fujimoto, Yohta Fukuda, Taku Yamashita, Tsuyoshi Inoue, Hirofumi Tsujino   +8 more
wiley   +1 more source

Real-world benchmarks for metastatic urothelial carcinoma: a single-center analysis of two standard immunotherapy pathways in Romania. [PDF]

Med Pharm Rep
Dulf DV, Burnar AL, Matei DR, Dulf PL, Hendea RM, Bungărdean C, Hopârtean A, Bolunduţ D, Andras I, Buzoianu M, Crişan N, Ciuleanu TE, Coadă CA.   +12 more
europepmc   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions. [PDF]

Cancers (Basel)
Pravisano F, Costa J, Marchi L, Pascoletti G, Poletto E, Del Vecchio M, Spagnoletti A, Cimminiello C, Papadopoulos N, Pigozzo J, Piccin L, Roccuzzo G, Fava P, Puglisi F, Aprile G, Minisini AM.   +15 more
europepmc   +1 more source